YMRC
UTHR icon

Yorktown Management & Research Company’s United Therapeutics UTHR Stock Holding History

Yorktown Management & Research Company’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-2,400
Closed -$281K – 421
2017
Q3 		$281K Buy
+2,400
New +$306K 0.07% 284
2016
Q2 		– Sell
-2,600
Closed -$290K – 366
2016
Q1 		$290K Buy
+2,600
New +$329K 0.06% 226

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Skandinaviska Enskilda Banken (SEB)
Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $4.34B AUM 19.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Yorktown Management & Research Company's UTHR Position: Q4 2017 in Review

Yorktown Management & Research Company sold out of United Therapeutics (UTHR) in Q4 2017, closing a stake of 2,400 shares — an estimated $281K sold.

Yorktown Management & Research Company first reported a position in UTHR in Q1 2016 and held it in 2 quarters. The position peaked at $290K in Q1 2016. 400 funds tracked by Wall St. Rank hold UTHR as of Q4 2017.

  • Yorktown Management & Research Company reported no remaining United Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Yorktown Management & Research Company sold 2,400 United Therapeutics shares in Q4 2017, an estimated $281K.
  • Yorktown Management & Research Company first reported a position in United Therapeutics in Q1 2016 and held it in 2 quarters.
  • Yorktown Management & Research Company's United Therapeutics position peaked at $290K in Q1 2016.
  • 400 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2017.

Based on Yorktown Management & Research Company's 13F filing for Q4 2017, filed 13 Feb 2018.